Results of the CONTROL Trial: Efficacy and Safety of Recombinant Activated Factor VII in the Management of Refractory Traumatic Hemorrhage.
Hauser, Carl J. MD; Boffard, Kenneth MD; Dutton, Richard MD; Bernard, Gordon R. MD; Croce, Martin A. MD; Holcomb, John B. MD; Leppaniemi, Ari MD; Parr, Michael MD; Vincent, Jean-Louis MD, PhD; Tortella, Bartholomew J. MD, MBA; Dimsits, Jeannett MD; Bouillon, Bertil MD; for the CONTROL Study Group
[Article] Journal of Trauma-Injury Infection & Critical Care. 69(3):489-500, September 2010.

(Format: HTML, PDF)

Background: Traumatic coagulopathy contributes to early death by exsanguination and late death in multiple organ failure. Recombinant Factor VIIa (rFVIIa, NovoSeven) is a procoagulant that might limit bleeding and improve trauma outcomes.

Methods: We performed a phase 3 randomized clinical trial evaluating efficacy and safety of rFVIIa as an adjunct to direct hemostasis in major trauma. We studied 573 patients (481 blunt and 92 penetrating) who bled 4 to 8 red blood cell (RBC) units within 12 hours of injury and were still bleeding despite strict damage control resuscitation and operative management. Patients were assigned to rFVIIa (200 [mu]g/kg initially; 100 [mu]g/kg at 1 hour and 3 hours) or placebo. Intensive care unit management was standardized using evidence-based trauma "bundles" with formal oversight of compliance. Primary outcome was 30-day mortality. Predefined secondary outcomes included blood products used. Safety was assessed through 90 days. Study powering was based on prior randomized controlled trials and large trauma center databases.

Results: Enrollment was terminated at 573 of 1502 planned patients because of unexpected low mortality prompted by futility analysis (10.8% vs. 27.5% planned/predicted) and difficulties consenting and enrolling sicker patients. Mortality was 11.0% (rFVIIa) versus 10.7% (placebo) (p = 0.93, blunt) and 18.2% (rFVIIa) versus 13.2% (placebo) (p = 0.40, penetrating). Blunt trauma rFVIIa patients received (mean /- SD) 7.8 /- 10.6 RBC units and 19.0 /- 27.1 total allogeneic units through 48 hours, and placebo patients received 9.1 /- 11.3 RBC units (p = 0.04) and 23.5 /- 28.0 total allogeneic units (p = 0.04). Thrombotic adverse events were similar across study cohorts.

Conclusions: rFVIIa reduced blood product use but did not affect mortality compared with placebo. Modern evidence-based trauma lowers mortality, paradoxically making outcomes studies increasingly difficult.

(C) 2010 Lippincott Williams & Wilkins, Inc.